RxDoctor Payments Data

Carol Pappas, MD

Neurology · St Petersburg, FLNPI 1659442101

Payments from drug & device makers

$90,906in general payments, 2019–2025

Across 348 payments — averaging $261.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$69K
  • Neurocrine Biosciences, Inc.$13K
  • Amneal Pharmaceuticals LLC$6K
  • Biogen$641
  • Acadia Pharmaceuticals Inc$300
  • Sunovion Pharmaceuticals Inc.$297
  • plus $2K from 30 others
$23,371in research payments, 2019–2025

Across 2 payments — averaging $11,686 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$23K

What the payments were for

  • Consulting fees$7,3509%
  • Speaking & faculty fees$59,09274%
  • Travel & lodging$6,5498%
  • Food & beverage$5,9257%
  • Education$1,4412%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,906 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$207,039
Medicare patients
544
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate26$133,123
OngentysOpicapone61$81,403
Austedo XrDeutetrabenazine12$69,793
NeuproRotigotine30$52,724
EliquisApixaban40$33,509
AptiomEslicarbazepine Acetate17$25,227
Memantine Hcl ErMemantine Hcl112$17,895
Rivastigmine40$9,408
RytaryCarbidopa/Levodopa16$8,632
Ropinirole ErRopinirole Hcl27$7,043
Pregabalin128$5,914
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone16$5,015
Carbidopa-LevodopaCarbidopa/Levodopa155$4,595
Desvenlafaxine Succinate ErDesvenlafaxine Succinate11$2,858
Donepezil Hcl72$2,662

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$300$133,12326 claims
Neurocrine Biosciences, Inc.Ongentys$12,629$81,40361 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$49$69,79312 claims
UCB, Inc.Neupro$205$52,72430 claims
PfizerEliquis$58$33,50940 claims
Sunovion Pharmaceuticals Inc.Aptiom$297$25,22717 claims
Amneal Pharmaceuticals LLCRytary$5,505$8,63216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.

Other neurology in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →